Leaderboards/gynecological conditions and treatments

gynecological conditions and treatments

Last updated June 2, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Herbert Tilg
Innsbruck Medical University
99
2
Giovanni Targher
University of Verona
90
3
Melissa M. Herbst‐Kralovetz
University of Arizona
80
4
Nicole R. Jimenez
University of Arizona
70
5
Wei‐Zhen Tang
Chongqing Medical University
60
6
Faezeh Ghorbanizamani
Ege University
40
7
Suna Tımur
Ege University
30

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Nadeem R. Abu‐Rustum
Cleveland Clinic
99
2
Monika Świerczewska
Heliodor Swiecicki Clinical Hospital
90
3
Lijun Yang
Chinese Academy of Medical Sciences & Peking Union Medical College
80
4
Marta Włodarczyk
Medical University of Warsaw
70
5
Sarah Teworte
University of Bern
60
6
Dileep Wijeratne
Leeds Teaching Hospitals NHS Trust
50
7
Wenli Cao
Unknown
40
8
Jennifer Le Guévelou
University of Geneva
30
9
Pınar Karadayı Ataş
Istanbul Arel University
20
10
Jung Chul Kim
Yonsei University
10

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Cristiana Sessa
Ospedale San Giovanni Bellinzona
99
2
Bradley J. Monk
The US Oncology Network
90
3
Angela W. Maina
Unknown
80
4
Takashi Kadowaki
The University of Tokyo
70
5
Rhonda Amsel
McGill University
60
6
Mahesh Parmar
MRC Clinical Trials Unit at UCL
50
7
V. Craig Jordan
Breast Cancer Care
40
8
Pedro F. Escobar
Cleveland Clinic
30
9
Charlotte Ellertson
Unknown
20
10
Muhammad B. Yunus
Illinois College
10

All-Time Leaders Papers

1
Adiponectin and Adiponectin Receptors
Endocrine Reviews|2005
2.6k cit.
2
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
The Lancet|2015
2k cit.
3
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
New England Journal of Medicine|2016
365 cit.
4
Glucokinase and IRS-2 are required for compensatory   cell hyperplasia in response to high-fat diet-induced insulin resistance
Journal of Clinical Investigation|2007
329 cit.
5
Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways
Journal of Biological Chemistry|2006
326 cit.
6
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Journal of Clinical Oncology|2020
151 cit.
7
TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass
Diabetologia|2013
86 cit.
8
Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice
Diabetologia|2012
85 cit.
9
Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity
Nature Communications|2018
77 cit.
10
Adiponectin/AdipoR Research and Its Implications for Lifestyle-Related Diseases
Frontiers in Cardiovascular Medicine|2019
71 cit.

Reagents for gynecological conditions and treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

Mena Antibody

#2075$317
View Evidence →Cell Signaling Technology

Tight Junction Antibody Sampler Kit

#8683$581
View Evidence →Cell Signaling Technology

CREB (D76D11) Rabbit Monoclonal Antibody

#4820$161
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

Progesterone Receptor

#M3569
View Evidence →Proteintech

Cytokeratin 19 antibody

#10712-1-AP$449
View Evidence →Cell Signaling Technology

Iba1/AIF-1 (E4O4W) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

#20825$183
View Evidence →